埃索美拉唑和雷贝拉唑有什么区别

(Nexium) magnesium enteric-coated tablets are drugs used to treat gastroesophageal diseases, while rabeprazole sodium enteric-coated capsules are also suitable for gastrointestinal diseases. Today we will learn more about the difference between esomeprazole and rabeprazole?

The active ingredient of Esomeprazole (Nexium) Magnesium Enteric-Coated Tablets is esomeprazole magnesium. Esomeprazole is the S-isomer of omeprazole. It reduces gastric acid secretion through a specific targeting mechanism and is a specific inhibitor of proton pumps in parietal cells. Esomeprazole magnesium enteric-coated tablets are suitable for the treatment of gastroesophageal reflux disease (GERD), erosive reflux esophagitis, and long-term maintenance treatment to prevent recurrence of cured esophagitis patients.

The main component of rabeprazole sodium enteric-coated capsules is rabeprazole sodium. Rabeprazole is a benzimidazole compound and a second-generation proton pump inhibitor. It blocks the final step of gastric acid secretion by specifically inhibiting the H+-K+ ATPase system of gastric parietal cells. This effect is dose-dependent and can inhibit both basal gastric acid secretion and gastric acid secretion under stimulation. This product has no antagonistic effect on choline and histamine H2 receptors. Rabeprazole sodium enteric-coated capsules are used to treat acid-related diseases, such as gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, Zollinger-Ellision syndrome, etc.

To compare the efficacy of esomeprazole (Nexium) quadruple therapy and rabeprazole quadruple therapy in eradicating Helicobacter pylori. Methods: 148 HP-positive patients were randomly divided into esomeprazole quadruple therapy group and rabeprazole quadruple therapy group. After corresponding treatment for 14 days, the Hp eradication rate was measured after 4 weeks of drug withdrawal. Results Results: The HP eradication rate in the esomeprazole (Nexium) quadruple therapy group was 91.8%, and the HP eradication rate in the bismuth quadruple therapy group was 73.0%. The difference in Hp eradication rates between the two groups was statistically significant (P<0.05). Conclusion: The anti-HP efficacy of esomeprazole quadruple therapy is better than that of rabeprazole quadruple therapy, and it is worthy of promotion.

In 2001, esomeprazole (Nexium) was approved by the FDA for marketing in the United States. On July 30, 2020, AstraZeneca announced that the China National Medical Products Administration (NMPA) officially approved esomeprazole (Nexium) injection for the prevention of stress ulcer bleeding in severe patients.

The above is the difference between (Nexium) and rabeprazole, I hope it can help you!

Recommended related hot articles: /newsDetail/71948.html